Home / FDA approval status
Prepared by: Research Desk. Sources are linked for verification.
Short answer: No. Retatrutide is an investigational drug. As of 18 October 2026 it is not approved by the U.S. Food and Drug Administration, and we know of no approval by any other major regulator. It is available legally only to people enrolled in clinical trials.
Here are the facts, each linked to its source.
Contents
Status summary
Question
Answer
Source
Can it be compounded in the U.S.?
No. FDA says it “cannot be used in compounding under federal law”
Has FDA found it safe and effective?
No. FDA says it has “not been found safe and effective for any condition”
What the FDA has said
The FDA’s page on unapproved GLP-1 drugs addresses retatrutide by name [1]:
“Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
The same page says FDA has warned:
telehealth companies for marketing retatrutide, including directly to consumers;
distributors for selling retatrutide to compounders;
outsourcing facilities for repackaging retatrutide [1].
Why “research use only” retatrutide is not a loophole
Products sold online as “retatrutide, for research purposes only, not for human consumption” have no FDA review of what is actually in the vial: its identity, purity, sterility or strength. FDA’s general position on unapproved GLP-1 products is that they “do not undergo FDA’s review for safety, effectiveness and quality before they are marketed” [1].
The safety data from the TRIUMPH trials come from drug made by the developer under controlled conditions, given with medical monitoring. Those results say nothing about a product of unknown origin. TripleReta does not link to, review or name any sellers.
Where the development program stands
The phase 3 program, called TRIUMPH, includes several trials registered on ClinicalTrials.gov:
Trial
Population
Registry status*
TRIUMPH-1 (NCT05929066)
Obesity or overweight, including knee osteoarthritis and sleep apnea substudies
*Registry statuses as shown on ClinicalTrials.gov when we checked on 18 October 2026.
When could retatrutide be approved?
Nobody outside the company and the FDA can give a firm date. Here is what we can say:
A company files a New Drug Application once it believes it has enough phase 3 data.
A standard FDA review takes about 10 months from filing, and a priority review about 6 months, though timelines vary.
An industry pipeline summary from May 2026 listed retatrutide among expected 2027 FDA decisions [4].
We’ll update this page when a filing or FDA acceptance is publicly confirmed.
Trials and expanded access
Clinical trials are the legal setting in which an investigational drug is studied. Retatrutide trials are listed on ClinicalTrials.gov, where open studies are marked “Recruiting”. Expanded access (sometimes called “compassionate use”) is a separate FDA pathway for serious conditions. Whether it is available for a particular drug depends on the company.
What we’ll update, and when
We’ll revise this page within a week of any of the following:
a public confirmation that a New Drug Application for retatrutide has been submitted or accepted by FDA;
publication of TRIUMPH-3, TRIUMPH-4 or TRIUMPH-5 results;
any new FDA statement or enforcement action naming retatrutide;
decisions by regulators outside the U.S.
Each update will carry a dated note at the bottom of the page, so you can see exactly what changed and when. If you spot something out of date, contact us through the About page.
Status checked: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.